Holowesko Partners’s AstraZeneca AZN Stock Holding History

Holowesko Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-28,500	Closed	-$1.99M	–	31
2018 Q1	$1.99M	Sell	28,500 -734,500	-96%	-$50.9M	0.14%	26
2017 Q4	$53M	Sell	763,000 -186,000	-20%	-$12.5M	3.34%	12
2017 Q3	$64.3M	Sell	949,000 -110,000	-10%	-$6.95M	5.12%	9
2017 Q2	$72.2M	Sell	1,059,000 -551,500	-34%	-$36M	4.87%	10
2017 Q1	$100M	Hold	1,610,500	–	–	6%	6
2016 Q4	$88M	Hold	1,610,500	–	–	6.15%	3
2016 Q3	$106M	Buy	1,610,500 +89,500	+6%	+$5.85M	9.46%	1
2016 Q2	$91.8M	Buy	1,521,000 +460,000	+43%	+$26.7M	7.72%	4
2016 Q1	$59.8M	Buy	1,061,000 +229,000	+28%	+$13.8M	4.33%	10
2015 Q4	$56.5M	Buy	+832,000	New	+$54.5M	3.68%	11

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Holowesko Partners's AZN Position: Q2 2018 in Review

Holowesko Partners sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 28,500 shares — an estimated $1.99M sold.

Holowesko Partners first reported a position in AZN in Q4 2015 and held it in 10 quarters. The position peaked at $106M in Q3 2016. 531 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Holowesko Partners reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
Holowesko Partners sold 28,500 AstraZeneca shares in Q2 2018, an estimated $1.99M.
Holowesko Partners first reported a position in AstraZeneca in Q4 2015 and held it in 10 quarters.
Holowesko Partners's AstraZeneca position peaked at $106M in Q3 2016.
531 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Holowesko Partners's 13F filing for Q2 2018, filed 10 Aug 2018.